IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026

As the genitourinary (GU) oncology world ramps up for the 2026 American Urological Association (AUA) Annual Meeting, OncLive® spoke with experts in the field to gain their perspectives regarding which sessions and presentations they are most looking forward to following during the meeting.

This exclusive preview includes insights from:

• Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky.
• Stephanie A. Berg, DO, a medical oncologist for the Lank Center of Genitourinary Oncology at Dana-Farber Cancer Institute, as well as an instructor in medicine at Harvard Medical School, both in Boston, Massachusetts.
• Shilpa Gupta, MD, director of the Genitourinary Medical Oncology at Taussig Cancer Institute and co-leader of the Genitourinary Oncology Program at Cleveland Clinic in Ohio.

“The 2026 meeting of the AUA is shaping up to be one of the most clinically consequential GU oncology meetings in recent years, with major updates expected across metastatic hormone-sensitive prostate cancer [mHSPC], androgen deprivation therapy [ADT] cardiovascular safety, and high-risk non–muscle invasive bladder cancer [NMIBC],” Park said.

P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Durvalumab with bacillus Calmette–Guérin therapy for high-risk non-muscle-invasive bladder cancer: expanded efficacy and safety analyses from POTOMAC

Presentation time: May 16, 2026, 2:35 pm ET

Park: Among bladder cancer presentations, the [phase 3] POTOMAC trial [NCT03528694] remains one of the most practice-changing datasets expected to receive major attention at AUA 2026.High-risk NMIBC remains one of the most frustrating disease states in GU oncology because recurrence rates remain substantial despite optimized BCG therapy. If approved, durvalumab plus BCG could become a new standard option for [patients with] BCG-naive high-risk NMIBC and potentially reshape treatment algorithms before progression to muscle-invasive disease. This study also arrives amid ongoing global BCG shortages, which continue to complicate NMIBC management.

Berg: This was already a positive study. I would like to see the longer[-term] safety data from immune checkpoint inhibitor exposure and if the rate of immune-related adverse effects were worse. Hopefully the disease-free survival benefit has been durable since [this study] was first presented at the 2025 ESMO Congress, [when it] already [had] a long follow-up of approximately 5 years.¹

PD23-02: Prostate-specific antigen endpoints in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive (PSMA+) metastatic hormone-sensitive prostate cancer (mHSPC)

Presentation time: May 17, 2026, 3:38 pm ET

Park: [The phase 3 PSMAddition] study [NCT04720157] originally drew major attention at ESMO 2025 when Scott T. Tagawa, MD, MS, FACP, FASCO, [of Weill Cornell Medicine in New York, New York,] presented the landmark primary analysis demonstrating a statistically significant improvement in radiographic progression-free survival.² Historically, PSMA-targeted radioligand therapy has largely been reserved for later-stage metastatic castration-resistant prostate cancer [mCRPC]. PSMAddition represents one of the clearest attempts to move radioligand therapy into earlier disease settings, where tumor burden may be more biologically sensitive and potentially more curable.

The emerging narrative from PSMAddition is no longer simply that radioligand therapy delays radiographic progression—it may also induce deeper biologic remissions earlier in the disease course. If longer follow-up confirms an overall survival benefit, PSMAddition could redefine frontline management of PSMA-positive mHSPC and accelerate movement toward [the integration of] quadruplet-style therapy approaches.

PD15-10: Examining the impact of TGF-b activity on fibroblast infiltration and immune exclusion in muscle-invasive bladder cancer

Presentation time: May 16, 2026, 4:34 pm ET

Gupta: I am presenting this [abstract] on oral TGF-beta [activity] in muscle-invasive bladder cancer.

PD23-10: Cardiovascular Consequences of Androgen Deprivation Therapy in Prostate Cancer Patients: A Short-Term Prospective Analysis

Presentation time: May 17, 2026, 4:34 pm ET

Park: Another highly relevant presentation at AUA 2026 is abstract PD23-10, evaluating cardiovascular consequences of ADT in prospective patients with prostate cancer. While ADT remains foundational in advanced prostate cancer management, increasing attention is being paid to its systemic toxicities—particularly cardiovascular complications.

AUA 2026 is expected to further amplify the shift toward cardio-oncology integration in prostate cancer management, particularly for elderly patients with competing cardiovascular risks. The broader message is becoming increasingly clear: survival gains in prostate cancer must now be balanced against long-term cardiovascular morbidity.

When does AUA 2026 begin?

The 2026 AUA Annual Meeting will commence on Friday, May 15, with presentations and sessions occurring daily through Monday, May 18. Follow OncLive throughout the meeting for coverage of key presentations and interviews live from Washington, DC.

“AUA 2026 is expected to reinforce a major shift in GU oncology toward earlier, deeper, and more biologically targeted treatment strategies,” Park said. “Taken together, the meeting highlights a field rapidly evolving beyond conventional hormone therapy alone, toward precision-guided multimodal treatment approaches designed not only to prolong survival, but also to optimize long-term outcomes and quality of life.”

References

1. De Santis M, Palou J, Nishiyama H, et al. Durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase III, open-label, randomised POTOMAC trial. Ann Oncol. 2025;36(suppl 2):S1650. doi:10.1016/j.annonc.2025.09.127
2. Tagawa ST, Sartor O, Piulats JM, et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Ann Oncol. 2025;36(suppl 2):S1627-S1628. doi:10.1016/j.annonc.2025.09.101